Molecular Health – Powered by grafiksuite Block Theme
-
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
-
Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer
-
Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
-
MH Guide as IVDR-certified product and part of your complete solution for NGS-based molecular tumor profiling
MH Guide is a clinical decision support software that assists molecular diagnostics by interpreting complex nextgeneration sequencing (NGS) datasets and translating the information into clinically relevant knowledge. This is particularly important for comprehensive genomic profiling (CGP) where multi-gene panels or whole exome sequencing result in large volumes of data that must be interpreted with confidence.…
-
Catalogue of peer-reviewed studies 2009 – 2023
Over the past decade and a half, Molecular Health has adopted an open innovation policy. This has resulted in successful collaborations with some of the world’s most renowned biomedical institutes and innovators. Together, we have tackled some of the most significant healthcare challenges, with Molecular Health providing the backbone of clinico-molecular data and cutting-edge analytical…
-
St. Marianna University School of Medicine in Japan relies on MH Guide for personalized cancer medicine
Heidelberg, Germany/Kawasaki, Japan, October 27, 2023 – St. Marianna University School of Medicine in Kawasaki, Japan, will utilize MH Guide to personalize cancer treatment. The agreement between University School of Medicine and Molecular Health resulted from a preceding study partnership.The MH Guide system has been previously implemented at St. Marianna University Hospital, and a proof-of-concept…
-
Molecular Health and Takara Bio collaborate to support Genome Medicine in Japan
Collaboration to introduce whole-genome sequencing with comprehensive variant annotation for Japanese patients affected by hereditary diseases.
-
Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study
-
Analysis and Clinical Relevance of Tumor Mutational Burden
Tumor mutational burden (TMB) is a genomic biomarker. In contrast to other biomarkers that are detected as a genomic alteration in a specific gene or via methods like immunohistochemistry, TMB is calculated. However, disagreements about calculation method, clinical indication for immunotherapy, and other factors have hindered establishment of TMB as a standardized biomarker.
-
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
-
Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide
-
Currently no job listings
We are always looking for new talent. Feel free to send us your CV. We’d love to get to know you! careers@molecularhealth.com
-
MH Guide 6.0: Next-level automation and precision in the clinical interpretation of cancer genomic profiling
Molecular Health has launched the latest version of its tertiary analysis solution for genomic profiling featuring improved variant classification and more targeted clinical trial matching.
-
Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms
-
Daten töten. Den Krebs.
-
Molecular Health receives IVDR certification for MH Guide
Molecular Health received certification from the European Union for its MH Guide clinical decision support software under the new In Vitro Diagnostics Regulation (EU) 2017/746 (IVDR).
-
Molecular Health and collaborators prove new analytical approach that leverages real-world data to anticipate molecular causation of adverse drug reactions
Molecular Health, the University of Florida, Takeda Oncology, and thinkQ2 published a triad of articles proving a novel systems approach to elucidate mechanisms of drug toxicities.
-
Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
-
Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics
-
Discover the benefits of automated variant annotation for your clinical routine
Automated variant interpretation – fast, precise, efficient MH Guide is an in-vitro diagnostic software approved in Europe. It assists molecular pathologists working with large molecular datasets. Independent of the sequencing technology used, MH Guide can interpret complex datasets and automatically identify genetic variants that are relevant for the treatment of cancer patients. This information is…
-
Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors
-
The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease
-
The earlier, the better – turning data into knowledge
Automated analysis of hereditary cancer predispositions Our applications for hereditary cancer predispositions are optimized for automated identification of clinically-significant germline variants associated with hereditary breast and ovarian cancers (HBOC), and other hereditary cancer predispositions.
-
Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey
Gen Era Diagnostics will provide the MH Guide software platform to twenty clinical laboratories in Turkey to use in the interpretation of tumor data for personalized cancer care.
-
Molecular Health and Essen University Hospital launch collaborative project to improve care for COVID-19 patients
In a three-part collaboration with the German Federal Ministry of Health, Molecular Health uses MH Corona Explorer to reveal the molecular basis of COVID-19 disease course.
-
Konyang University Hospital in South Korea relies on MH Guide for personalized cancer medicine
Konyang University Hospital uses MH Guide to perform comprehensive analyses of genes, clinical information, and drugs to provide world-class precision cancer care.
-
Wir bringen die biologische Grammatik in die Medizin
-
Target adverse event profiles for predictive safety in the postmarket setting
-
MH Guide: Molecular tumor diagnostics in 7 steps
The MH Guide software supports therapy decisions in oncology. It can translate data obtained from molecular tumor diagnostic tests into clinically relevant knowledge. This overview illustrates the practical use of the MH Guide.
-
Panel diagnostics instead of hotspot? Here are the differences
NGS, WGS, SNV – What do these abbreviations stand for in molecular pathological diagnostics? What are the benefits of NGS-based panel diagnostics in oncology? This overview provides answers regarding methods of molecular tumor diagnostic testing.
-
Molecular Health – intelligent solutions for smarter healthcare
-
70-year-old with recurrent ovarian cancer
After several therapies and relapses, a 70-year-old female patient with advanced ovarian cancer experienced renewed progression. The use of Molecular Health Guide (MH Guide) provided the molecular tumor board with comprehensive insights and individual therapeutic recommendations.
-
MH Guide: six questions and answers
Tailor-made cancer treatments based on molecular target structures – that’s the premise of personalized tumor therapy. Software-supported solutions like MH Guide can help pinpoint addressable biomarkers as well as treatment options. Read on for answers to the most common questions about MH Guide.
-
Molecular Health and FALCO biosystems team up to provide genetic analysis services using MH Guide/BRCA and MH Guide/Mendel
FALCO biosystems Ltd. will use the products MH Guide/BRCA and MH Guide/Mendel to evaluate inherited genetic variants of BRCA1/2 and other heritable cancer-associated genes.
-
Molekulare Diagnostik beim Mammakarzinom – Wo stehen wir auf dem Weg zur molekular stratifizierten Therapie?
-
Datenprojekt zu Covid-Langzeitfolgen startet
-
Wie der MH Corona Explorer die Versorgung COVID-19-Kranker verbessern soll
-
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development